medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

The effect of metabolic traits on oral and oropharyngeal cancer risk: a Mendelian randomization analysis

Mark Gormley, BDS* [1,2], Tom Dudding, PhD[2], Steven J Thomas, PhD[2], Jessica Tyrrell, PhD[3], Andrew R Ness, PhD[4], Miranda Pring, PhD[2], Danny Legge, PhD[5], George Davey Smith, FRS[1], Rebecca C Richmond, PhD[1], Emma E Vincent, PhD[1,5§], Caroline Bull, PhD[1,5§]

[1] MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

[2] Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

[3] University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

[4] University Hospitals Bristol and Weston NHS Foundation Trust National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol, Bristol, UK

[5] Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

§ Joint senior authors

* Corresponding author: mark.gormley@bristol.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Abstract

Introduction

A recent World Health Organization report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors. Established risk factors for head and neck cancer include tobacco use, alcohol consumption and human papillomavirus infection. Given the significant decline in smoking rates, particularly within developing countries, other potentially modifiable risk factors warrant investigation. Obesity and related metabolic disorders such as type 2 diabetes and hypertension have all been associated with head and neck cancer risk in multiple observational studies. However, obesity has also been correlated with other major head and neck cancer risk factors such as smoking, meaning independent effects are difficult to establish. Furthermore, selection bias, confounding or reverse causality may explain the findings from observational studies.

Methods

To overcome the challenges of observational studies, we conducted two-sample Mendelian randomization (inverse variance weighted (IVW) method) using genetic variants which were robustly associated with obesity, T2D and hypertension in genome-wide association studies (GWAS). Outcome data was taken from the largest available GWAS of 6,034 oral and oropharyngeal cases, with 6,585 controls.

Results

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

We found limited evidence of a causal effect of genetically proxied body mass index (OR IVW 0.89, 95%CI 0.72–1.09, p = 0.26 per 1 SD in BMI (4.81 kg/m2)) on combined oral and oropharyngeal cancer risk. Similarly, there was limited evidence for genetically-proxied T2D (OR IVW 0.92, 95%CI 0.84–1.01, p = 0.09 per 1-log unit higher odds of T2D), or related traits including fasting glucose and insulin. Higher HbA1c resulted in a weak protective effect on combined oral and oropharyngeal cancer risk (OR IVW 0.56, 95%CI 0.32–1.00, p = 0.05 per 1-log-unit % higher HbA1c), which was not robust to sensitivity testing. Finally, there was limited evidence for an effect of systolic blood pressure on combined oral and oropharyngeal cancer risk (OR IVW 1.00, 95%CI 0.97–1.03, p = 0.89 per 1 unit mmHg increase). Smoking also appears to act as a mediator in the relationship between obesity and HNC in instrument-risk factor analyses.

Conclusion

This analysis suggests the possibility that the effect of metabolic disorders may have been previously overestimated in observational studies. However, these cannot be directly compared given the differences in methodologies and the interpretation of estimates.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Introduction

Head and neck squamous cell carcinoma (HNC), which includes cancers of the oral cavity and oropharynx is the 7th most common cancer, accounting for more than 660,000 new cases and 325,000 deaths annually worldwide [1,2]. Established risks include tobacco use, alcohol consumption [3] and human papillomavirus (HPV) infection, mainly associated with oropharyngeal cancer and thought to be sexually transmitted [4]. A recent World Health Organization (WHO) report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors [5]. Smoking behaviour is declining, particularly in developing countries and it has been projected that obesity could even supersede smoking as the primary driver of cancer in the coming decades [5]. Despite changes in smoking rates, the incidence of HNC continues to rise and a changing aetiology has been proposed [6,7]. Therefore, less established risks such as obesity and its related metabolic traits warrant investigation in HNC. However, obesity has been correlated with other HNC risk factors such as smoking [8], alcohol [9] and educational attainment [10], meaning independent effects are difficult to establish.

Obesity is now considered to increase the risk of at least 13 different types of cancer including breast, colorectal, gastric and oesophageal [11], but the effect on HNC risk remains unclear [5]. Public health strategies have been unsuccessful in addressing the current obesity epidemic at the population level, which could result in more cancer cases in the years to come [12]. Obesity and related metabolic traits such as type 2 diabetes (T2D), hypertension and dyslipidaemia have all been associated with head and neck cancer in multiple

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

observational studies. In the largest pooled analysis, obesity defined by higher body mass index (BMI) was associated with a protective effect for HNC in current smokers (hazard ratio (HR) 0.76, 95% confidence intervals (95%CI) 0.71–0.82, p <0.0001, per 5 kg/m^2) and conversely, a higher risk in never smokers (HR 1.15, 95%CI 1.06–1.24 per 5 kg/m^2, p < 0.001) [13]. In the same study, a greater waist circumference (WC) (HR 1.04, 95%CI 1.03–1.05 per 5 cm, p < 0.001) and waist-to-hip ratio (WHR) (HR 1.07, 95%CI 1.05–1.09 per 0.1 unit, p < 0.001) were associated with increased HNC risk, which did not vary by smoking status [13]. However, more recent cohort studies have failed to show a clear association between BMI and HNC [14-18]. A meta-analysis of observational studies investigating T2D with oral and oropharyngeal subsites, showed an increased risk ratio (RR) of 1.15, 95%CI 1.02–1.29, *P heterogeneity* = 0.277 [19], a result which is consistent with more recent independent cohorts [14,20-22]. Hypertension (defined as a systolic blood pressure (SBP) > 130 mmHg or diastolic blood pressure (DBP) > 85 mmHg), has been correlated with head and neck cancer risk across multiple studies [21-25]. Nonetheless, selection bias, confounding, or reverse causation may explain the findings from these studies.

Mendelian randomization (MR) is an analytical approach which attempts to overcome the challenges of conventional epidemiological studies. The method uses germline genetic single nucleotide polymorphisms (SNPs), which are randomly assorted during meiosis (and fixed at conception), to estimate the causal effects of exposures on disease outcomes [26-28]. Using MR, we recently found limited evidence for a role of circulating lipid traits in oral and oropharyngeal cancer risk [29], however other metabolic traits remain untested in an MR framework. Here, we employ a two-sample MR approach, integrating summary-level genetic data from the largest available GWAS for metabolic traits, including obesity

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

measures (BMI, WC, WHR), glycaemic traits (T2D, glycated haemoglobin (HbA_{1c}), fasting glucose (FG), fasting insulin (FI)), and blood pressure (SBP, DBP) to evaluate their causal effect on oral and oropharyngeal cancer risk. Given the potential correlation of metabolic traits and established HNC risk factors, further evaluation of instrument-risk factor effects including smoking, alcohol, risk tolerance (as a proxy for sexual behaviour), and educational attainment was carried out using MR.

Methods

Two-sample MR was performed using published summary-level data from the largest available GWAS for each metabolic trait. MR makes three key assumptions, as described in **Fig. 1** [26,27].



Figure 1. Directed acyclic graph (DAG) depicting Mendelian randomization applied to this study

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Genetic variants (G) act as proxies or instruments to investigate if an exposure (X), is associated with a trait e.g., body mass index or disease outcome (Y) e.g., oral/oropharyngeal cancer. Causal inference can be made between X and Y if the following conditions are upheld:

(1) G is a valid instrument, reliably associated with X ('relevance');

(2) no measured (C) or unmeasured (U) confounding of the association between G and the Y ('exchangeability');

(3) there is no independent association of G with Y, except through X ('exclusion restriction principle').

Exposure summary statistics for metabolic traits

To instrument metabolic traits, we selected genetic variants associated ($p < 5 \times 10^{-8}$) with traits of interest identified by previously conducted GWAS (**Supplementary Data 1**). Clumping was performed to ensure single nucleotide polymorphisms (SNPs) in each instrument were independent (linkage disequilibrium $R^2 < 0.001$). Following clumping, genetic instruments were comprised of: 312 SNPs for BMI, from a GWAS meta-analysis of 806,834 individuals of European ancestry, including the Genetic Investigation of ANthropometric Traits (GIANT) consortium and UK Biobank [30]; 45 SNPs for WC, extracted from the same GWAS [30]; 209 SNPs for WHR extracted from a GWAS meta-analysis describing 224,459 individuals of mainly European ancestry [31]; 275 SNPs for T2D from the DIAMANTE (DIAbetes Meta-ANalysis of Trans-Ethnic association studies) consortium of 228,499 cases and 1,178,783 controls [32]; 33 SNPs for FG and 18 SNPs for FI, obtained from a GWAS published by the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium (N = 151,188 and 105,056 individuals, respectively) [33]; 58 SNPs for HbA_{1c}, taken from a meta-analyses of 159,940 individuals from 82 cohorts of European, African, East Asian, and

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

South Asian ancestry [34]; Finally, 105 and 78 SNPs for SBP and DBP, respectively, were extracted from a GWAS meta-analysis of over 1 million participants in UK Biobank and the International Consortium of Blood Pressure Genome Wide Association Studies (ICBP) [35] (**Supplementary Data 1**).

Outcome summary statistics for oral and oropharyngeal cancer

We estimated the effects of metabolic traits on risk of oral and oropharyngeal cancer by extracting exposure SNPs (**Supplementary Data 1**) from the largest available GWAS performed on 6,034 cases and 6,585 controls from 12 studies which were part of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network [36]. Full details of the included studies, as well as the genotyping and imputation performed, have been described previously [36,37]. In brief, the study population included participants from Europe (45.3%), North America (43.9%) and South America (10.8%). Cancer cases comprised the following the International Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9, C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code (other). A total of 954 individuals with cancers of hypopharynx, unknown code or overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray, custom designed for cancer studies by the OncoArray Consortium [38]. Principle components analysis was performed using approximately 10,000 common markers in low LD ($r^2 < 0.004$), minor allele frequency (MAF) > 0.05 and 139 population outliers were removed.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Given the differential association of potential risk factors at each subsite (i.e. smoking, alcohol and HPV infection)[6], we performed stratified MR analyses for oral and oropharyngeal cancer to evaluate potential heterogeneity in effects. For this, we used GWAS summary data on a subset of 2,990 oral and 2,641 oropharyngeal cases and the 6,585 common controls in the GAME-ON GWAS [36].

Statistical analysis

Two-sample MR was conducted using the "TwoSampleMR" package in R (version 3.5.3), by integrating SNP associations for each metabolic trait (exposure, sample 1) with those for oral and oropharyngeal cancer in GAME-ON (outcome, sample 2). We only used genetic variants reaching GWAS significance ($p < 5\times10^{-8}$). The nearest gene was identified using SNPsnap and a distance of +/- 500 kb [39]. Firstly, metabolic trait-associated SNPs were extracted from oral and oropharyngeal cancer summary statistics. Exposure and outcome summary statistics were harmonised using the "*harmonise_data*" function of the TwoSampleMR package so that variant effect estimates corresponded to the same allele. Palindromic SNPs were identified and corrected using allele frequencies where possible (alleles were aligned when minor allele frequencies were < 0.3, or were otherwise excluded). For each SNP in each exposure, individual MR effect-estimates were calculated using the Wald method (SNP-outcome beta/SNP-exposure beta) [40]. Multiple SNPs were then combined into multi-allelic instruments using random-effects inverse-variance weighted (IVW) meta-analysis.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

IVW estimates may be vulnerable to bias if genetic instruments are invalid and are only unbiased in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced [41]. We therefore performed additional sensitivity analyses to evaluate the potential for unbalanced horizontal pleiotropy using weighted median [42], weighted mode [43] and MR-Egger [44] methods which are described in detail elsewhere [45]. In short, the weighted median stipulates that at least 50% of the weight in the analysis stems from valid instruments. Weighted mode returns an unbiased estimate of the causal effect if the cluster with the largest weighted number of SNPs for the weighted model are all valid instruments. Instruments are weighted by the inverse variance of the SNP-outcome association.[43]

Finally, MR-Egger provides reliable effect estimates even if variants are invalid and the Instrument Strength Independent of Direct Effect (InSIDE) assumption is violated [44]. The InSIDE assumption states that the association between genetic instrument and exposure should not be correlated with an independent path from instrument to the outcome. In the presence of unbalanced pleiotropy when the InSIDE assumption is violated, then the MR-Egger result may be biased [45]. Gene variants must be valid instruments and where there was evidence of violation of the negligible measurement error (NOME) assumption [46], this was assessed using the I^2 statistic and MR-Egger was performed with simulation extrapolation (SIMEX) correction for bias adjustment [46]. The variance of each trait explained by the genetic instrument (R^2) was estimated and used to perform power calculations [47]. F-statistics were also generated. An F-statistic lower than 10 was interpreted as indicative of a weak instrument bias [48]. To further assess the robustness of MR estimates, we examined evidence of heterogeneity across individual SNPs using the Cochran Q-statistic, which indicates the presence of invalid instruments (e.g., due to horizontal pleiotropy), if Q is much larger than

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

its degrees of freedom (No. of instrumental variables minus 1) [49]. MR-PRESSO (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and correct for potential outliers (where Q-statistic $p < 0.05$) [50].

Instrument-risk factor effects

Where there was evidence for an effect of a metabolic trait on oral or oropharyngeal cancer risk in the primary MR analysis, we conducted further evaluation of the metabolic instruments onto established HNC risk factors using two-sample MR. The largest available GWAS were used for smoking initiation (a binary phenotype indicating whether an individual had ever smoked in their life versus never smokers) (n=1,232,091) and alcoholic drinks per week (defined as the average number of drinks per week aggregated across all types of alcohol, n=941,280) from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) study [51]. Summary statistics were also obtained from a GWAS of general risk tolerance (n=939,908), derived from a meta-analysis of UK Biobank (n=431,126) binary question *"Would you describe yourself as someone who takes risks?"* and the 23andMe (n=508,782) question *"Overall, do you feel comfortable or uncomfortable taking risks?"*. The GWAS of risk tolerance was based on one's tendency or willingness to take risks, making them more likely to engage in risk-taking behaviours more generally [52]. A strong genetic correlation between sexual behaviours and risk tolerance has been shown previously [53]. Finally, given the known association between HNC and lower socioeconomic position, we used MR to examine educational attainment (defined by years of schooling) [54]. Outcome beta estimates reflect the standard deviation of the phenotype.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Results

F-statistics of genetic instruments for metabolic traits ranged from 33.3 – 133.6, indicating sufficient instrument strength for MR analyses (**Supplementary Table 1**). Genetic instruments were estimated to explain between 0.5% (FI) and 4% (BMI) of their respective metabolic trait (**Supplementary Table 1**). Based on the results of prior observational studies we would expect to detect OR of >1.10 for a clinically meaningful effect of metabolic traits on oral and oropharyngeal cancer. **Supplementary Fig. 1A-C** displays power estimates for MR analyses. In analyses where BMI was the exposure, we had 70% power to detect an association with an OR of 1.2 or more at an α of 0.05 for combined oral and oropharyngeal cancer. Power was lower for other metabolic traits and reduced when stratifying analyses by subsite (**Supplementary Fig. 1**).

Estimated effect of adiposity on oral and oropharyngeal cancer risk

There was limited evidence of an effect of higher BMI or WHR on combined oral and oropharyngeal cancer (OR IVW 0.89, 95%CI 0.72–1.09, p = 0.26, per 1 SD in BMI (4.81 kg/m^2) and OR IVW 0.98, 95%CI 0.74–1.29, p = 0.88, per 1 SD in WHR (0.10 unit)) (**Table 1; Fig. 2; Supplementary Fig. 2 & 3**). Results were consistent when analyses were stratified by subsite (**Table 1**). WC, another measure of adiposity did show a protective direction of effect (OR IVW 0.73, 95%CI 0.52–1.02, p = 0.07, per 1 SD increase in WC (0.09 unit)), particularly in the oropharyngeal subsite (OR IVW 0.66, 95%CI 0.43–1.01, p = 0.06, per 1 SD increase in WC (0.09 unit)) (**Table 1; Fig. 2; Supplementary Fig. 4**).

Estimated effect of glycaemic traits on oral and oropharyngeal cancer risk

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

There was limited evidence for an effect of genetically-proxied T2D on combined oral and oropharyngeal cancer (OR IVW 0.92, 95%CI 0.84–1.01, p = 0.09, per 1-log unit higher odds of T2D (**Table 1; Fig. 2; Supplementary Fig. 5**). Traits related to diabetes, including HbA_{1c} resulted in a weak protective effect on combined oral and oropharyngeal cancer risk (OR IVW 0.56, 95%CI 0.32–1.00, p = 0.05, per 1-log-unit % higher HbA_{1c}), which remained only in the oral subsite (OR IVW 0.48, 95%CI 0.24–0.93, p = 0.03, per 1-log-unit % higher HbA_{1c}) following stratification (**Table 1; Fig. 2; Supplementary Fig. 6**). Conversely, there was limited evidence of an effect for FG (OR IVW 1.06, 95%CI 0.68–1.66, p = 0.79, per 1-log unit increase in mmol/L fasting glucose) (**Table 1; Fig. 2; Supplementary Fig. 7**) or FI (OR IVW 0.81, 95%CI 0.23–2.89, p = 0.75, per 1-log unit increase in mmol/L fasting insulin) on combined oral and oropharyngeal cancer risk (**Table 1; Fig. 2; Supplementary Fig. 8**)

Estimated effect of increased blood pressure oral and oropharyngeal cancer risk

Finally, there was limited evidence for an effect of SBP on risk of combined oral and oropharyngeal cancer (OR IVW 1.00, 95%CI 0.97–1.03, p = 0.89, per 1 unit mmHg increase in systolic blood pressure) (**Table 1; Fig. 2; Supplementary Fig. 9**), which did not change when stratified by subsite. However, there was some weak evidence for a protective effect of DBP on risk of combined oral and oropharyngeal cancer (OR IVW 0.93, 95%CI 0.87–1.00, p = 0.05, per 1 unit mmHg increase in diastolic blood pressure) (**Table 1; Fig. 2; Supplementary Fig. 10**).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

295 **Table 1.** Mendelian randomization results of genetically-proxied metabolic traits with risk of oral and oropharyngeal cancer in GAME-ON

					IVW		Weighted median		Weighted mode		MR-Egger	
Exposure	**Outcome**	**Exposure/ Outcome source**	**Outcome N**	**Number of SNPs**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**
BMI	Oral and oropharyngeal cancer combined	Pulit *et al.* GWAS [30]/ GAME-ON [36]	6,034	272	0.89 (0.72, 1.09)	0.26	0.71 (0.50, 1.00)	0.05	0.63 (0.37, 1.04)	0.07	0.66 (0.40, 1.10)	0.11
	Oral cancer		2,990	272	0.92 (0.71, 1.19)	0.53	0.83 (0.55, 1.28)	0.40	0.79 (0.38, 1.62)	0.52	0.75 (0.39, 1.41)	0.37
	Oropharyngeal cancer		2,641	272	0.89 (0.68, 1.15)	0.36	0.75 (0.50, 1.13)	0.17	0.53 (0.27, 1.03)	0.06	0.56 (0.29, 1.07)	0.08
WC	Oral and oropharyngeal cancer combined	Pulit *et al.* GWAS [30]/ GAME-ON [36]	6,034	43	0.73 (0.52, 1.02)	0.07	0.64 (0.40, 1.05)	0.08	0.67 (0.36, 1.26)	0.22	0.43 (0.17, 1.08)	0.08
	Oral cancer		2,990	43	0.82 (0.53, 1.26)	0.36	0.66 (0.36, 1.21)	0.18	0.67 (0.32, 1.39)	0.29	0.54 (0.17, 1.76)	0.31
	Oropharyngeal cancer		2,641	43	0.66 (0.43, 1.01)	0.06	0.56 (0.30, 1.05)	0.07	0.37 (0.17, 0.83)	0.02	0.30 (0.09, 0.98)	0.05
WHR	Oral and oropharyngeal cancer combined	Shungin *et al.* GWAS [31]/ GAME-ON [36]	6,034	176	0.98 (0.74, 1.29)	0.88	0.98 (0.64, 1.49)	0.92	0.95 (0.45, 2.00)	0.89	1.80 (0.87, 3.71)	0.11
	Oral cancer		2,990	176	1.18 (0.84, 1.65)	0.35	1.00 (0.58, 1.73)	0.99	0.69 (0.29, 1.67)	0.41	2.49 (1.02, 6.12)	0.05
	Oropharyngeal cancer		2,641	176	0.83 (0.59, 1.14)	0.25	0.88 (0.51, 1.50)	0.63	0.93 (0.37, 2.30)	0.87	1.19 (0.50, 2.86)	0.70
T2D	Oral and oropharyngeal cancer combined	Vujkovic *et al.* GWAS [32]/ GAME-ON [36]	6,034	254	0.92 (0.84, 1.01)	0.09	0.85 (0.74, 0.97)	0.02	0.84 (0.71, 1.01)	0.06	0.91 (0.77, 1.09)	0.31
	Oral cancer		2,990	254	0.94 (0.84, 1.05)	0.27	0.84 (0.72, 0.99)	0.04	0.82 (0.66, 1.02)	0.08	0.88 (0.71, 1.08)	0.22
	Oropharyngeal cancer		2,641	254	0.94 (0.84, 1.05)	0.27	0.89 (0.73, 1.10)	0.29	1.02 (0.80, 1.30)	0.88	1.00 (0.81, 1.24)	0.99
HbA_{1c}	Oral and oropharyngeal cancer combined	Wheeler *et al.* GWAS [34]/ GAME-ON [36]	6,034	37	0.56 (0.32, 1.00)	0.05	0.52 (0.23, 1.20)	0.12	0.54 (0.24, 1.21)	0.14	0.37 (0.13, 1.05)	0.07
	Oral cancer		2,990	37	0.48 (0.24, 0.93)	0.03	0.51 (0.18, 1.41)	0.19	0.44 (0.15, 1.29)	0.14	0.30 (0.09, 1.03)	0.06
	Oropharyngeal cancer		2,641	37	0.66 (0.31, 1.40)	0.28	0.49 (0.15, 1.57)	0.23	0.57 (0.18, 1.85)	0.35	0.43 (0.11, 1.68)	0.23
	Oral and oropharyngeal		6,034	28	1.06 (0.68, 1.66)	0.79	1.20 (0.62, 2.30)	0.59	1.13 (0.60, 2.12)	0.71	1.11 (0.48, 2.56)	0.80

FG	cancer combined	Lagou *et al.* GWAS [33]/ GAME-ON [36]										
	Oral cancer		2,990	28	1.05 (0.58, 1.92)	0.87	1.15 (0.48, 2.72)	0.75	0.99 (0.44, 2.23)	0.99	1.25 (0.39, 4.01)	0.70
	Oropharyngeal cancer		2,641	28	1.39 (0.77, 2.51)	0.28	1.24 (0.51, 3.03)	0.63	1.36 (0.59, 3.18)	0.48	1.38 (0.45, 4.18)	0.58
FI	Oral and oropharyngeal cancer combined	Lagou *et al.* GWAS [33]/ GAME-ON [36]	6,034	17	0.81 (0.23, 2.89)	0.75	0.75 (0.20, 2.87)	0.68	0.60 (0.03, 10.79)	0.74	0.11 (0.001, 22.47)	0.43
	Oral cancer		2,990	17	0.96 (0.22, 4.16)	0.96	0.46 (0.08, 2.47)	0.37	0.45 (0.01, 19.02)	0.68	0.21 (0.0004, 107.21	0.63
	Oropharyngeal cancer		2,641	17	0.68 (0.16, 2.87)	0.59	0.66 (0.12, 3.67)	0.63	0.48 (0.05, 4.99)	0.55	0.09 (0.0002, 40.04)	0.45
SBP	Oral and oropharyngeal cancer combined	Evangelou *et al.* GWAS [35]/ GAME-ON [36]	6,034	83	1.00 (0.97, 1.03)	0.89	0.99 (0.94, 1.03)	0.55	0.98 (0.88, 1.09)	0.66	1.06 (0.92, 1.23)	0.39
	Oral cancer		2,990	83	1.01 (0.96, 1.06)	0.74	0.99 (0.93, 1.04)	0.65	0.95 (0.84, 1.08)	0.48	1.09 (0.90, 1.33)	0.37
	Oropharyngeal cancer		2,641	83	0.99 (0.95, 1.03)	0.65	0.99 (0.94, 1.05)	0.77	1.00 (0.88, 1.13)	0.94	1.03 (0.87, 1.23)	0.71
DBP	Oral and oropharyngeal cancer combined	Evangelou *et al.* GWAS [35]/ GAME-ON [36]	6,034	64	0.93 (0.87, 1.00)	0.05	0.94 (0.86, 1.04)	0.22	1.10 (0.88, 1.38)	0.42	0.99 (0.80, 1.24)	0.95
	Oral cancer		2,990	64	0.95 (0.87, 1.04)	0.26	0.96 (0.86, 1.07)	0.45	1.17 (0.88, 1.56)	0.28	0.97 (0.74, 1.27)	0.81
	Oropharyngeal cancer		2,641	64	0.92 (0.84, 1.00)	0.05	0.94 (0.84, 1.05)	0.29	1.10 (0.86, 1.41)	0.45	1.00 (0.75, 1.30)	0.93

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, *p*-value; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA_{1c}, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m^2), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA_{1c} (1-log-unit % higher glycated haemoglobin), SBP (1 unit mmHg increase) and DBP (1 unit mmHg increase).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Figure 2. Mendelian randomization results of genetically-proxied metabolic disorders with risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON



Abbreviations: IVW, inverse variance weighted; OR, odds ratio with 95% confidence intervals; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m2), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA1c (1-log-unit % higher glycated haemoglobin), SBP (1 unit mmHg increase) and DBP (1 unit mmHg increase).

Sensitivity analyses

We conducted MR Egger, weighted median, and weighted mode analyses in addition to IVW (**Table 1; Fig. 2**). The results of these analyses generally followed the same pattern as the

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

IVW results reported above, however, there were a number of exceptions. The results for HbA1c were not robust to sensitivity testing (p > 0.05 across methods) (**Table 1; Fig. 2**). In the analysis of T2D on combined oral and oropharyngeal cancer, the weighted median result provided evidence for a weak protective effect (OR weighted median 0.85, 95%CI 0.74–0.97, *p* = 0.02). This effect appeared mainly in the oral subsite (OR weighted median 0.84, 95%CI 0.72–0.99, *p* = 0.04). Furthermore, in the analysis of WC on oropharyngeal cancer risk, the weighted mode supported IVW result, providing evidence of a protective effect (OR weighted mode 0.37, 95%CI 0.17–0.83, *p* = 0.02) (**Table 1; Fig. 2**).

There was clear evidence of heterogeneity in the SNP effect estimates for IVW and MR Egger regression for WHR (Q IVW 213.04, *p* = 0.03; Q MR Egger 209.24, *p* = 0.04), T2D (Q IVW 328.24, p < 0.01; Q MR Egger 328.21, *p* < 0.01), FI (Q IVW 32.87, *p* < 0.01; Q MR Egger 31.63, *p* < 0.01) and DBP (Q IVW 95.82 *p* < 0.01; Q MR Egger 95.22, *p* < 0.01) (**Supplementary Table 2**). MR-Egger intercepts were not strongly indicative of directional pleiotropy (**Supplementary Table 3**), but there were outliers present on visual inspection of scatter plots (**Supplementary Figs. 11-19**). MR-PRESSO identified 19 outliers for BMI, 2 outliers for WC, 12 outliers for WHR, 23 outliers for T2D, 4 outliers for HbA_{1c}, 1 outlier for FG, 3 outliers for FI, 5 outliers for SBP, 7 outliers for DBP (**Supplementary Tables 4-5**). When correcting for these outliers, this yielded effects consistent with the primary IVW analysis except for adiposity and T2D instruments, which demonstrated a protective effect on combined oral and oropharyngeal cancer risk when outliers were excluded: BMI (OR IVW 0.77, 95%CI 0.62–0.94, *p* = 0.01, per 1 SD in BMI (4.81 kg/m^2)); WC (OR IVW 0.65, 95%CI 0.47–0.89, *p* = 0.01, per 1 SD in WC (0.09 unit)), and T2D (OR IVW 0.91, 0.84–0.99, *p* = 0.03, per 1-log unit higher odds of T2D) (**Supplementary Table 6**). Where there was evidence of

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

violation of the NOME assumption for WC, FI, SBP and DBP (i.e., I^2 statistic <0.90) (**Supplementary Table 7**), MR-Egger was performed with SIMEX correction. SIMEX effects were consistent with the null, except for SBP where an increased risk effect on combined oral and oropharyngeal cancer was found (OR IVW 1.15, 95%CI 1.05–1.26, $p < 0.01$, per 1 unit mmHg increase in diastolic blood pressure) (**Supplementary Table 8**).

Evaluating instrument-risk factor effects

Where there was some evidence for an effect of BMI, WC, WHR , T2D , HbA_{1c} and DBP on oral and oropharyngeal cancer, we carried out further MR analysis to determine causal effects of these metabolic instruments on established risk HNC risk factors. Obesity-related measures showed a strong causal effect on the risk of smoking initiation: BMI (Beta IVW 0.21 (standard error (SE) 0.03), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m2)), WC (Beta IVW 0.21 (SE 0.05), $p < 0.001$, per 1 SD increase in WC (0.09 unit)) and WHR (Beta IVW 0.18 (SE 0.03), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)) (**Supplementary Table 9**). There was weaker evidence for an effect of BMI, WC, and genetic liability to T2D on consumption of alcoholic drinks per week: BMI (Beta IVW -0.04 (SE 0.01), $p < 0.01$, per 1 SD increase in BMI (4.81 kg/m2)), WC (Beta IVW -0.09 (SE 0.02), p < 0.001, per 1 SD increase in WC (0.09 unit)) and T2D (Beta IVW -0.02 (SE 0.01), $p < 0.001$, per 1-log unit higher odds of T2D). BMI (Beta IVW 0.04 (SE 0.01), $p <0.001$, per 1 SD increase in BMI (4.81 kg/m2)) and WHR (Beta IVW 0.04 (SE 0.02), $p = 0.02$, per 1 SD increase in WHR (0.10 unit)) were also estimated to increase general risk tolerance. Similarly, increased BMI or WHR and genetic liability to T2D were estimated to increase educational attainment (years of schooling): BMI (Beta IVW -0.16 (SE 0.02), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m2)), WHR (Beta IVW -0.11 (SE 0.02), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)), and T2D (Beta IVW -0.02 (SE 0.01), p

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

< 0.01, per 1-log unit higher odds of T2D). However, there was strong evidence of both heterogeneity (**Supplementary Table 10**) and genetic pleiotropy (**Supplementary Table 11**) across most instrument-risk factor effects. With the exception of alcohol drinks per week, the estimated instrument-risk factor effects remained unchanged following the removal of outlier SNPs detected by MR-PRESSO (**Supplementary Table 12**).

Discussion

In this MR study we found limited evidence to support a causal role of genetically-predicted metabolic traits in oral and oropharyngeal cancer, suggesting the risk may have been previously overestimated in observational studies. Where weak evidence for an effect was found (i.e., a protective effect of HbA_{1c}), these results were not robust to sensitivity analysis, including outlier correction. There was also strong evidence for instrument-risk factor effects, suggesting smoking may be a mediator between obesity and HNC.

There are several biological mechanisms linking metabolic traits and cancer, but these have not been well explored in HNC [55-57]. Dysregulated metabolism is likely linked to the probability a cancer develops and progresses, given that tumours must adapt to satisfy the bioenergetic and biosynthetic demands of chronic cell proliferation via metabolic reprogramming, enhancing or suppressing the activity of metabolic pathways relative to that in benign tissue [58]. In the largest pooled analysis of 17 case-control studies, BMI was associated with a higher risk of overall HNC, but when stratified by subsite the effect was mainly in the larynx (HR 1.42, 95%CI 1.19–1.70 per 5 kg/m^2, $p < 0.001$) [13]. Laryngeal cancer

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

was not included in our study given that GWAS summary data were not available for this subsite and future analysis of this region is therefore warranted. BMI effects on both the oral (HR 1.10, 95%CI 0.97–1.25, $p = 0.14$) and oropharyngeal cancer (HR 0.98, 95%CI 0.84–1.14, $p = 0.77$) subsites were consistent with the effects found in our study (oral cancer OR 0.92, 95%CI 0.71–1.19, $p = 0.53$; oropharyngeal cancer OR 0.89, 0.68–1.15, $p = 0.36$) [13]. Conversely, the same pooled analysis found an increased risk for both WC (HR 1.09, 95%CI 1.03–1.16, $p = 0.006$) and WHR (HR 1.17, 95%CI 1.02–1.34, $p = 0.02$), mainly in the oral subsite which were not replicated in our MR analysis. Varying patterns of results for these anthropometric measures have been found when stratifying by smoking status within observational studies [13]. The relationship between obesity and HNC is complex. There appears to be a positive association between low BMI (<18.5 kg/m^2) and HNC risk, and a protective effect of BMI on HNC risk in current smokers but conversely, a higher risk in never smokers [13]. This suggests smoking is a confounder, both as an established risk factor for HNC and in its correlation with weight, with nicotine affecting metabolic energy expenditure, leading to reduced calorie absorption and appetite suppression [59]. Instrument-risk factor effect estimates from this study suggest smoking is also a mediator, through which metabolic traits such as BMI influence HNC risk.

Despite metabolic syndrome (including hypertension, central obesity, elevated triglyceride, low HDL-C and insulin resistance) being strongly associated with common cancers such as colorectal and breast [60], this does not appear to be the case in head and neck cancer. A recent prospective study of 474,929 participants from UK Biobank investigating the effect of metabolic syndrome suggested those with the condition had no increased HNC risk (HR 1.05, 95%CI 0.90–1.22, $p = 0.560$) [14]. No definitive causal effects were detected for

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

individual components of metabolic syndrome components either, supporting our MR results. While another large meta-analysis found individuals with T2D have an elevated risk of oral cancer [19], other more recent studies have found this effect to be mostly in laryngeal subsite (HR 1.25, 95%CI 1.12–1.40) which again we could not investigate in this study [21]. Hypertension is the most consistently reported metabolic trait to have an observational association with HNC risk across the subsites [21-25]. We did not identify a clear effect of either SBP or DBP on oral or oropharyngeal cancer using MR, again suggesting the possibility of residual confounding in observational studies.

MR was employed in this study in an attempt to overcome the drawbacks of conventional epidemiological studies. However, there are a number of limitations with using this approach and if MR assumptions are violated, this too can generate spurious conclusions. While there was no evidence of weak instrument bias (F statistics > 10), there was heterogeneity present in at least four of the instruments (WHR, T2D, FI and DBP). This is expected to some extent, given that we are instrumenting multiple biological pathways that contribute to complex metabolic phenotypes. The use of multiple related instruments for each metabolic trait may, however, provide some additional confidence in the overall findings. Given the low percentage of variation explained (R^2) for some instruments, as well as the relatively small number of oral and oropharyngeal cancer cases, power to detect an effect may have been an issue in some of our analyses.

As with observational studies, there may be issues of measurement error or misclassification in genetic epidemiology, given BMI is simply a function of mass and height and does not specifically measure adiposity. However, BMI has been shown to be an

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

acceptable proxy when used in large samples sizes, correlating with both total body fat [61] and total abdominal adipose tissue [62], which is thought to present a greater health risk than fat deposited elsewhere. Furthermore, we used a range of adiposity measures including WC and WHR, which may be better proxies of abdominal adiposity, compared to BMI [63]. SNPs used to proxy these metabolic traits, particularly obesity-related measures BMI, WC and WHR were strongly associated with smoking. Given the heterogeneity of these complex metabolic traits, future work could further examine their pathway specific effects [64].

Conclusion

Overall, there was limited evidence for an effect of genetically-proxied metabolic traits on oral and oropharyngeal cancer risk. These findings suggest metabolic traits may not be effective modifiable risk factors to prioritise as part of future prevention strategies in head and neck cancer. The effect of metabolic traits on the risk of this disease may have been overestimated in previous observational studies, but these cannot be directly compared given the differences in methodological approaches and the interpretation of estimates. Smoking appears to act as a mediator in the relationship between obesity and HNC. Although there is no clear evidence that changing body mass will reduce of increase the risk of HNC directly, dental and medical teams should be aware of the risk of smoking in those who are overweight and therefore the greater risk of cancer when providing smoking cessation and appropriate weight loss advice.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

References

1 Sung, H. *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, doi:https://doi.org/10.3322/caac.21660 (2021).

2 Johnson, D. E. *et al.* Head and neck squamous cell carcinoma. *Nature Reviews Disease Primers* **6**, 92, doi:10.1038/s41572-020-00224-3 (2020).

3 Hashibe, M. *et al.* Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. *Cancer Epidem Biomar* **18**, 541-550, doi:10.1158/1055-9965.Epi-08-0347 (2009).

4 Gillison, M. L., Chaturvedi, A. K., Anderson, W. F. & Fakhry, C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin Oncol* **33**, 3235-3242, doi:10.1200/JCO.2015.61.6995 (2015).

5 World Health Organization (WHO). *WHO European Regional Obesity Report 2022. [Internet] [cited 2022 Jun 06]*, 2022).

6 Thomas, S. J., Penfold, C. M., Waylen, A. & Ness, A. R. The changing aetiology of head and neck squamous cell cancer: A tale of three cancers? *Clin Otolaryngol* **43**, 999-1003, doi:10.1111/coa.13144 (2018).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

7 Conway, D. I., Purkayastha, M., Chestnutt, I. G. The changing epidemiology of oral cancer: definitions, trends, and risk factors. *British Dental Journal* **225**, 867-873, doi:10.1038/sj.bdj.2018.922 (2018).

8 Carreras-Torres, R. *et al.* Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank. *BMJ (Clinical research ed.)* **361**, k1767-k1767, doi:10.1136/bmj.k1767 (2018).

9 Carter, A. R. *et al.* Combined Association of Body Mass Index and Alcohol Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: A Mendelian Randomization Study. *JAMA Network Open* **2**, e190305-e190305, doi:10.1001/jamanetworkopen.2019.0305 (2019).

10 Carter, A. R. *et al.* Understanding the consequences of education inequality on cardiovascular disease: mendelian randomisation study. *BMJ* **365**, l1855, doi:10.1136/bmj.l1855 (2019).

11 Centers for Disease Control and Prevention. *Obesity and Cancer [Internet] [cited 2022 Jun 18],* <https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20or%20having%20obesity,the%20United%20States%20each%20year.> (2021).

12 Davey, R. C. The obesity epidemic: too much food for thought? *British Journal of Sports Medicine* **38**, 360-363, doi:10.1136/bjsm.2003.007443 (2004).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

13 Gaudet, M. M. *et al.* Anthropometry and head and neck cancer:a pooled analysis of cohort data. *Int J Epidemiol* **44**, 673-681, doi:https://dx.doi.org/10.1093/ije/dyv059 (2015).

14 Jiang, H. *et al.* The effect of metabolic syndrome on head and neck cancer incidence risk: a population-based prospective cohort study. *Cancer & metabolism* **9**, 25-25, doi:https://dx.doi.org/10.1186/s40170-021-00261-w (2021).

15 Diaz, Y. *et al.* Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. *BMC Medicine* **19**, 10-10, doi:http://dx.doi.org/10.1186/s12916-020-01877-3 (2021).

16 Cao, Z. *et al.* Association of obesity status and metabolic syndrome with site-specific cancers: a population-based cohort study. *Brit J Cancer* **123**, 1336-1344, doi:http://dx.doi.org/10.1038/s41416-020-1012-6 (2020).

17 Gribsholt, S. B. *et al.* Hospital-diagnosed overweight and obesity related to cancer risk: a 40-year Danish cohort study. *Journal of Internal Medicine* **287**, 435-447, doi:http://dx.doi.org/10.1111/joim.13013 (2020).

18 Ward, H. A. *et al.* Measured Adiposity in Relation to Head and Neck Cancer Risk in the European Prospective Investigation into Cancer and Nutrition. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* **26**, 895-904, doi:https://dx.doi.org/10.1158/1055-9965.EPI-16-0886 (2017).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

19 Gong, Y., Wei, B., Yu, L. & Pan, W. Type 2 diabetes mellitus and risk of oral cancer and precancerous lesions: a meta-analysis of observational studies. *Oral oncology* **51**, 332-340, doi:https://dx.doi.org/10.1016/j.oraloncology.2015.01.003 (2015).

20 Saarela, K. *et al.* Cancer incidence among Finnish people with type 2 diabetes during 1989-2014. *Eur J Epidemiol* **34**, 259-265, doi:https://dx.doi.org/10.1007/s10654-018-0438-0 (2019).

21 Kim, H.-B., Kim, G.-J., Han, K.-d. & Joo, Y.-H. Changes in metabolic syndrome status and risk of laryngeal cancer: A nationwide cohort study. *PLoS ONE* **16**, e0252872-e0252872, doi:http://dx.doi.org/10.1371/journal.pone.0252872 (2021).

22 Kim, S.-Y., Han, K.-d. & Joo, Y.-H. Metabolic Syndrome and Incidence of Laryngeal Cancer: A Nationwide Cohort Study. *Scientific reports* **9**, 667, doi:https://dx.doi.org/10.1038/s41598-018-37061-0 (2019).

23 Stocks, T. *et al.* Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. *Hypertension (Dallas, Tex. : 1979)* **59**, 802-810, doi:https://dx.doi.org/10.1161/HYPERTENSIONAHA.111.189258 (2012).

24 Christakoudi, S. *et al.* Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* **146**, 2680-2693, doi:http://dx.doi.org/10.1002/ijc.32576 (2020).

25 Seo, J.-H., Kim, Y.-D., Park, C.-S., Han, K.-d. & Joo, Y.-H. Hypertension is associated with oral, laryngeal, and esophageal cancer: a nationwide population-based study.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Scientific reports **10**, 10291, doi:https://dx.doi.org/10.1038/s41598-020-67329-3 (2020).

26 Smith, G. D. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* **32**, 1-22, doi:10.1093/ije/dyg070 (2003).

27 Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* **23**, R89-98, doi:10.1093/hmg/ddu328 (2014).

28 Sanderson, E. *et al.* Mendelian randomization. *Nature Reviews Methods Primers* **2**, 6, doi:10.1038/s43586-021-00092-5 (2022).

29 Gormley, M. *et al.* Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study. *PLOS Genetics* **17**, e1009525, doi:10.1371/journal.pgen.1009525 (2021).

30 Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* **28**, 166-174, doi:10.1093/hmg/ddy327 (2019).

31 Shungin, D. *et al.* New genetic loci link adipose and insulin biology to body fat distribution. *Nature* **518**, 187-196, doi:10.1038/nature14132 (2015).

32 Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet* **52**, 680-691, doi:10.1038/s41588-020-0637-y (2020).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

33 Lagou, V. *et al.* Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. *Nature Communications* **12**, 24, doi:10.1038/s41467-020-19366-9 (2021).

34 Wheeler, E. *et al.* Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. *PLoS Med* **14**, e1002383, doi:10.1371/journal.pmed.1002383 (2017).

35 Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet* **50**, 1412-1425, doi:10.1038/s41588-018-0205-x (2018).

36 Lesseur, C. *et al.* Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. *Nat Genet* **48**, 1544-1550, doi:10.1038/ng.3685 (2016).

37 Dudding, T. *et al.* Assessing the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal cancer using Mendelian randomization. *Int J Cancer* **143**, 1029-1036, doi:10.1002/ijc.31377 (2018).

38 Consortium, O. Consortium launches genotyping effort. *Cancer Discov* **3**, 1321-1322, doi:10.1158/2159-8290.CD-NB2013-159 (2013).

39 Pers, T. H., Timshel, P. & Hirschhorn, J. N. SNPsnap: a Web-based tool for identification and annotation of matched SNPs. *Bioinformatics* **31**, 418-420, doi:10.1093/bioinformatics/btu655 (2014).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

40 Wald, A. The Fitting of Straight Lines if Both Variables are Subject to Error. *The Annals of Mathematical Statistics* **11**, 284-300, 217 (1940).

41 Hemani, G., Bowden, J. & Smith, G. D. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum Mol Genet* **27**, R195-R208, doi:10.1093/hmg/ddy163 (2018).

42 Bowden, J., Smith, G. D., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* **40**, 304-314, doi:10.1002/gepi.21965 (2016).

43 Hartwig, F. P., Smith, G. D. & Bowden, J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* **46**, 1985-1998, doi:10.1093/ije/dyx102 (2017).

44 Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* **44**, 512-525, doi:10.1093/ije/dyv080 (2015).

45 Lawlor DA, W. K., Borges MC, Palmer T, Hartwig FP, Hemani G, Bowden JA. . A Mendelian Randomization dictionary: Useful definitions and descriptions for undertaking, understanding and interpreting Mendelian Randomization studies. doi:doi:10.31219/osf.io/6yzs7 (2019).

46 Bowden, J. *et al.* Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I-2 statistic. *Int J Epidemiol* **45**, 1961-1974, doi:10.1093/ije/dyw220 (2016).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

47 Brion, M. J., Shakhbazov, K. & Visscher, P. M. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol* **42**, 1497-1501, doi:10.1093/ije/dyt179 (2013).

48 Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med* **27**, 1133-1163, doi:10.1002/sim.3034 (2008).

49 Bowden, J. *et al.* Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. *Int J Epidemiol* **47**, 1264-1278, doi:10.1093/ije/dyy101 (2018).

50 Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Publisher Correction: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* **50**, 1196, doi:10.1038/s41588-018-0164-2 (2018).

51 Liu, M. Z. *et al.* Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237, doi:10.1038/s41588-018-0307-5 (2019).

52 Karlsson Linner, R. *et al.* Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. *Nat Genet* **51**, 245-257, doi:10.1038/s41588-018-0309-3 (2019).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

53 Gormley, M. *et al.* Investigating the effect of sexual behaviour on oropharyngeal cancer risk: a methodological assessment of Mendelian randomization. *BMC Medicine* **20**, 40, doi:10.1186/s12916-022-02233-3 (2022).

54 Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet* **50**, 1112-1121, doi:10.1038/s41588-018-0147-3 (2018).

55 Tseng, K. S., Lin, C., Lin, Y. S. & Weng, S. F. Risk of head and neck cancer in patients with diabetes mellitus: a retrospective cohort study in Taiwan. *JAMA Otolaryngol Head Neck Surg* **140**, 746-753, doi:10.1001/jamaoto.2014.1258 (2014).

56 Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* **4**, 891-899, doi:10.1038/nrc1478 (2004).

57 Grimberg, A. Mechanisms by which IGF-I may promote cancer. *Cancer Biol Ther* **2**, 630-635 (2003).

58 DeNicola, G. M. & Cantley, L. C. Cancer's Fuel Choice: New Flavors for a Picky Eater. *Mol Cell* **60**, 514-523, doi:10.1016/j.molcel.2015.10.018 (2015).

59 Williamson, D. F. *et al.* Smoking Cessation and Severity of Weight Gain in a National Cohort. *New Engl J Med* **324**, 739-745, doi:10.1056/nejm199103143241106 (1991).

60 Esposito, K., Chiodini, P., Colao, A., Lenzi, A. & Giugliano, D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. *Diabetes care* **35**, 2402-2411, doi:10.2337/dc12-0336 (2012).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

61 Browning, L. M. *et al.* Measuring abdominal adipose tissue: comparison of simpler methods with MRI. *Obes Facts* **4**, 9-15, doi:10.1159/000324546 (2011).

62 Ross, R., Léger, L., Morris, D., de Guise, J. & Guardo, R. Quantification of adipose tissue by MRI: relationship with anthropometric variables. *J Appl Physiol (1985)* **72**, 787-795, doi:10.1152/jappl.1992.72.2.787 (1992).

63 Lee, C. M., Huxley, R. R., Wildman, R. P. & Woodward, M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. *J Clin Epidemiol* **61**, 646-653, doi:10.1016/j.jclinepi.2007.08.012 (2008).

64 Udler, M. S. *et al.* Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. *PLoS Med* **15**, e1002654, doi:10.1371/journal.pmed.1002654 (2018).

Ethics approval and consent to participate

All studies included as part of the GAME-ON network obtained approval and consent from their respective institutions.

Consent for publication

Not applicable.

Availability of data and materials

Summary-level analysis was conducted using publicly available GWAS data as cited. Full summary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

2017 at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202.v1.p1). There is one selected publication by Lesseur et al. related to this data [36]. Exposure data is publicly available from the relevant studies and via the IEU Open GWAS (https://gwas.mrcieu.ac.uk/). MR analyses were conducted using the "TwoSampleMR" package in R (version 3.5.3). A copy of the code and all files used in this analysis is available at GitHub (https://github.com/MGormley12/metabolic_trait_hnc_mr.git).

Competing interests

The authors declare that they have no competing interests

Funding

M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC research fellow at the University of Bristol. J.T. is supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, Global Challenges Research Fund (GCRF), the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). A.R.N. was supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National Institute for Health Research (NIHR) and is a partnership between University Hospitals Bristol NHS Foundation Trust and the University

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

of Bristol. Department of Health and Social Care disclaimer: The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This publication presents data from the Head and Neck 5000 which contributes to international VOYAGER and HEADSpAcE head and neck cancer consortia. The Head and Neck 5000 study was a component of independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Core funding was also provided through awards from Above and Beyond, University Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A20919). The VOYAGER study was supported in part by the US National Institute of Dental and Craniofacial Research (NIDCR; R01 DE025712). The genotyping of the HNC cases and controls was performed at the Center for Inherited Disease Research (CIDR) and funded by the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). E.E.V, C.B. and D.L. are supported by Diabetes UK (17/0005587). E.E.V, and C.B. are supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009). M.G., T.D., G.D.S, E.E.V., R.C.R, and C.B. are part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/5, MC_UU_00011/6, MC_UU_00011/7).

Authors' contributions

medRxiv preprint doi: https://doi.org/10.1101/2022.08.10.22278617; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

M.G., E.E.V., R.C.R. and C.B. conceived the study and M.G. carried out data curation and analysis. Head and neck cancer summary genetic data was obtained through multiple collaborations from studies lead by A.R.N., S.J.T., and M.P. as well as members of VOYAGER and HEADSpAcE consortia. The initial manuscript was drafted by M.G., E.E.V. and C.B.. Expert guidance on MR methodology was provided by T.D., C.B. and G.D.S. All authors M.G., T.D., S.J.T., J.T., A.R.N., M.P., D.L., G.D.S., R.C.R., E.E.V., and C.B. contributed to the interpretation of the results and critical revision of the manuscript. All authors read and approved the final manuscript. M.G. supervisory team includes R.C.R., E.E.V., J.T., A.R.N and G.D.S.